The roles of VHL-dependent ubiquitination in signaling and cancer

Qing Zhang1* and Haifeng Yang2*

1 Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
2 Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA

*Correspondence: Qing Zhang, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, Meyer Building, Room 457, Boston, MA 02215, USA. e-mail: qing_zhang@dfci.harvard.edu;
Haifeng Yang, Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, NB-40, 9500 Euclid Avenue, Cleveland, OH 44195, USA. e-mail: yangh2@ccf.org

von HIPPEL–LINDAU (VHL), THE REGULATION OF THE ALPHA SUBUNITS OF HYPOXIA-INDUCIBLE FACTOR, AND OXYGEN SENSING

Loss of function of the tumor suppressor gene VHL is causal in the pathogenesis of clear cell renal cell carcinoma (ccRCC). The vast majority (70–80%) of sporadic RCCs are pathologically characterized as ccRCC. Among them, approximately 70% harbor bi-allelic inactivation of VHL through mutation, deletion, or hyper-methylation of promoter (Kaelin, 2002; Linehan and Zbar, 2004). Inherited germline mutations in VHL predispose these patients to bilateral kidney cancer earlier than the sporadic kidney cancer patients, since the loss of the remaining wild type allele occurs more readily than the loss of two alleles. The protein product of the VHL tumor suppressor gene, pVHL, is found to be the substrate recognition unit of an E3 ubiquitin ligase complex that contains Cullin 2 (Cul2), Elongin B and C, and Rbx1 (Kamura et al., 1999a,b). Interestingly, tumor-derived point mutations were found to cluster around substrate recognizing (α domain) sites (Stebbins et al., 1999), stressing the importance of ubiquitin ligase activity to pVHL's tumor suppressor function. This complex targets the α subunits of the heterodimeric transcription factor hypoxia-inducible factor (HIF) for ubiquitination and proteasome-mediated degradation (Ohh et al., 2000). In addition to being a part of an E3 ubiquitin ligase complex, pVHL also regulates other HIF-independent biological processes such as inhibition of NF-κB activity (Yang et al., 2007), maintenance of chromosome stability (Thoma et al., 2009), and promoting cilia production (Schraml et al., 2009), which will not be reviewed in this article.

The function of tumor suppressor VHL is compromised in the vast majority of clear cell renal cell carcinoma, and its mutations or loss of expression was causal for this disease. pVHL was found to be a substrate recognition subunit of an E3 ubiquitin ligase, and most of the tumor-derived mutations disrupt this function. pVHL was found to bind to the alpha subunits of hypoxia-inducible factor (HIF) and promote their ubiquitination and proteasome degradation. Proline hydroxylation on key sites of HIFα provides the binding signal for pVHL E3 ligase complex. Beside HIFα, several other VHL targets have been identified, including activated epidermal growth factor receptor (EGFR), RNA polymerase II subunits RPβ1 and hsRPβ7, atypical protein kinase C (PKC), Sprouty2, β-adrenergic receptor II, and Myb-binding protein p160. HIFα is the most well studied substrate and has been proven to be critical for pVHL's tumor suppressor function, but the activated EGFR and PKC and other pVHL substrates might also be important for tumor growth and drug response. Their regulations by pVHL and their relevance to signaling and cancer are discussed.

Keywords: ubiquitin, VHL, HIF, ccRCC, EGFR, proline hydroxylation
HIF targets contribute to kidney tumor growth and maintenance. Stitutively active HIF2α and kidney tumors found clever ways to inactivate them (Dalgliesh et al., 2010; Kucejova et al., 2011). Further careful analysis of how (H3K4Me3; Niu et al., 2012). Both were tumor-suppressive events, decreased the overall level of the trimethylated histone H3 lysine 4 (H3K4Me3).

HIF-dependent activation of REDD1 suppressed mTORC1 downstream effectors and elicited biological responses (Yarden and Slawkowski, 2001). Ras/Raf/MEK/ERK and PI3K/PDK1/Akt1 are two major downstream pathways of activated EGFR. Since they promote both cellular proliferation and resistance to apoptosis (Iorissen et al., 2003), failure to turn off the activated EGFR can drive tumorigenesis.

Endocytosis and lysosome-mediated degradation is reported to be the major mechanism to down-regulate the activated EGFR. By binding to EGFR either directly through phosphorylated Y1045 (Levkowitz et al., 1999) or through its association with another EGFR-interacting protein Grb2 (Waterman et al., 2002), the ubiquitin ligase c-Cbl promotes its ubiquitination (Levkowitz et al., 1998). c-Cbl promotes mono-ubiquitylation on multiple lysine residues of EGFR, which is sufficient for EGFR endocytosis and degradation (Haglund et al., 2003a,b; Mosesson et al., 2003). However, mass-spectrometric and western blot analyses have suggested that a fraction of activated EGFR is poly-ubiquitinated (Huang et al., 2006; Umebayashi et al., 2008). Thus it is possible that other E3 ubiquitin ligases add poly-ubiquitin to the activated EGFR to promote its turnover.

Recently it was reported that pVHL was essential for the clearance of activated EGFR (Wang et al., 2009) and the proposed mechanism was that constitutively active HIF suppressed the lysosomal-mediated degradation of the activated EGFR. Specifically, Wang et al. suggested that HIF reduced the expression of Rabaptin-5. As Rabaptin-5 is critical for Rab5-mediated endosome fusion, reduced expression of Rabaptin-5 led to delayed EGFR sorting to the late endosome and lysosome, and this led to longer half-lives of the activated EGFR. This explanation predicted that delayed turnover of activated EGFR in VHL-defective ccRCC cells was due to high levels of HIFα subunits. However, Zhou and Yang (2011) found that the endogenous HIF was not the only or major cause of delayed EGFR turnover in VHL-defective ccRCC cells. Furthermore, they found that pVHL-mediated down-regulation of the activated EGFR was mostly mediated by proteasome instead of lysosome. In addition, loss of both c-Cbl and VHL caused the activated EGFR to become completely stable during the experiment, suggesting that these ubiquitin ligases collaborated to down-regulate activated EGFR. Finally it was reported that pVHL promoted the poly-ubiquitination of the activated EGFR, and this persisted in the absence of c-Cbl. Thus in ccRCC cells, pVHL promotes the poly-ubiquitination of the activated EGFR.

Endothelial growth factor (VEGF), a critical HIF target gene, promotes angiogenesis (Smith et al., 2006; Umebayashi et al., 2008). Thus it is possible that other E3 ubiquitin ligases add poly-ubiquitin to the activated EGFR to promote its turnover.

ACTIVATED EPIDERMAL GROWTH FACTOR RECEPTOR

It is known that HIF can enhance epidermal growth factor receptor (EGFR) activity to promote tumor growth (de Paulsen et al., 2001; Franovic et al., 2007). In VHL-defective ccRCC cells, the expression of transforming growth factor-α (TGF-α), an agonist to EGFR, is induced by HIF2α. This stimulates cell proliferation through an autocrine loop (de Paulsen et al., 2001). At the same time, constitutively active HIF2α also increases the translational efficiency of EGFR mRNA (Franovic et al., 2007). Increased EGFR expression and elevated TGF-α work together to promote autonomous growth (cellular growth in the absence of stimulating growth factors), which is a hallmark of cancer. Stable suppression of EGFR by shRNAs prevents serum-free growth of VHL-defective ccRCC cells in vitro, and retards the tumor growth of these cells for extended periods in vivo without affecting HIF2α functions (Smith et al., 2005; Lee et al., 2008). This suggests that EGFR is critical for the tumor growth of VHL-defective ccRCC cells and could be a good therapeutic target in kidney cancer.

Epidermal growth factor receptor is implicated in many human cancers, as activating mutations of EGFR have been identified in human glioblastoma, non-small cell lung carcinomas (NSCLC), and colon cancer. Upon ligand binding, EGFR and its family members homo- or hetero-dimerize, trans-phosphorylate the c-terminal tyrosine residues. These phosphorylated residues recruit signaling molecules, which activate downstream effectors and elicit biological responses (Yarden and Slawkowski, 2001). Ras/Raf/MEK/ERK and PI3K/PDK1/Akt1 are two major downstream pathways of activated EGFR. Since they promote both cellular proliferation and resistance to apoptosis (Iorissen et al., 2003), failure to turn off the activated EGFR can drive tumorigenesis.

Endocytosis and lysosome-mediated degradation is reported to be the major mechanism to down-regulate the activated EGFR. By binding to EGFR either directly through phosphorylated Y1045 (Levkowitz et al., 1999) or through its association with another EGFR-interacting protein Grb2 (Waterman et al., 2002), the ubiquitin ligase c-Cbl promotes its ubiquitination (Levkowitz et al., 1998). c-Cbl promotes mono-ubiquitylation on multiple lysine residues of EGFR, which is sufficient for EGFR endocytosis and degradation (Haglund et al., 2003a,b; Mosesson et al., 2003). However, mass-spectrometric and western blot analyses have suggested that a fraction of activated EGFR is poly-ubiquitinated (Huang et al., 2006; Umebayashi et al., 2008). Thus it is possible that other E3 ubiquitin ligases add poly-ubiquitin to the activated EGFR to promote its turnover.

Recently it was reported that pVHL was essential for the clearance of activated EGFR (Wang et al., 2009) and the proposed mechanism was that constitutively active HIF suppressed the lysosomal-mediated degradation of the activated EGFR. Specifically, Wang et al. suggested that HIF reduced the expression of Rabaptin-5. As Rabaptin-5 is critical for Rab5-mediated endosome fusion, reduced expression of Rabaptin-5 led to delayed EGFR sorting to the late endosome and lysosome, and this led to longer half-lives of the activated EGFR. This explanation predicted that delayed turnover of activated EGFR in VHL-defective ccRCC cells was due to high levels of HIFα subunits. However, Zhou and Yang (2011) found that the endogenous HIF was not the only or major cause of delayed EGFR turnover in VHL-defective ccRCC cells. Furthermore, they found that pVHL-mediated down-regulation of the activated EGFR was mostly mediated by proteasome instead of lysosome. In addition, loss of both c-Cbl and VHL caused the activated EGFR to become completely stable during the experiment, suggesting that these ubiquitin ligases collaborated to down-regulate activated EGFR. Finally it was reported that pVHL promoted the poly-ubiquitination of the activated EGFR, and this persisted in the absence of c-Cbl. Thus in ccRCC cells, pVHL promotes the poly-ubiquitination of the activated EGFR.

Prominent features even when the oxygen supply is not limited. In the xenograft models of ccRCC, constitutive HIF activation was both sufficient (Kondo et al., 2002) and necessary for tumor growth (Kondo et al., 2003; Zimmer et al., 2004). In the clinic trials, drugs that block the activities of the receptors for vascular endothelial growth factor (VEGF), a critical HIF target gene, produced clear and positive, albeit often transient, clinical outcomes in kidney cancer patients (Rini, 2005).

Interestingly, although HIF2α is a potent oncogene, the activations of HIF targets are not necessarily all tumor-promoting events. HIF-dependent activation of REDD1 suppressed mTORC1 (Kucejova et al., 2011), and HIF-dependent activation of JARID1C decreased the overall level of the trimethylated histone H3 lysine 4 (H3K4Me3; Niu et al., 2012). Both were tumor-suppressive events, and kidney tumors found clever ways to inactivate them (Dalgliesh et al., 2010; Kucejova et al., 2011). Further careful analysis of how HIF targets contribute to kidney tumor growth and maintenance might yield new ways to treat kidney cancer.
lated proline, promotes the ubiquitination of RPB1, and reduces these data suggest that pVHL binds to RPB1 through hydroxylation on RPB1 led to its proline hydroxylation. They also showed that the amount of hyperphosphorylated, but not hypophosphorylated RPB1, is unique to kidney cancer cells.

Large subunit of RNA polymerase II (RPB1) is responsible for the initiation and elongation of mRNA and its activity is regulated through its c-terminal phosphorylation. Kuznetsova et al. (2003; Table 1). Through bioinformatic analysis, Kuznetsova et al. (2003) found that a fragment of RPB1 share some sequence similarity with oxygen-dependent degradation domain (ODDD) of HIF1α. In addition, RPB1 also contained an analogous LXXLAP sequence that was found in HIF1α protein that was the site of prolyl hydroxylation that mediated recognition by pVHL. In response to DNA damage agents or UV radiation, RPB1 underwent hyperphosphorylation and then proline hydroxylation. This led to recognition by pVHL-associated E3 ligase complex and its ubiquitination in PC12 cells. By testing the in vitro binding between RPB1 peptide and radio-labeled pVHL, they showed that hydroxylated RPB1 Proline 1465 was the major site that mediated interaction with pVHL. However, it remained to be determined whether hyperphosphorylation on RPB1 led to its proline hydroxylation. They also showed that the amount of hyperphosphorylated, but not hypophosphorylated RPB1 correlates inversely with pVHL levels in PC12 cells. These data suggest that pVHL binds to RPB1 through hydroxylated proline, promotes the ubiquitination of RPB1, and reduces hyperphosphorylated RPB1 levels in response to UV or DNA damage agents in PC12 cells.

Surprisingly, when pVHL was re-expressed in two different VHL-deficient kidney cancer cell lines, pVHL increased the level of RPB1 instead of decreasing it as expected (Mikhailova et al., 2008). Furthermore, overexpression of wild type RPB1, not the P1465A mutant that cannot be hydroxylated, promoted tumor growth in kidney cancer cells expressing wild type VHL. Since the P1465A mutant RPB1 escapes VHL regulation, this is against the hypothesis that loss of VHL regulation on RPB1 is a tumor-promoting event. However, subsequent studies did reveal that RPB1 hydroxylation was significantly higher in kidney tumors compared to normal control. Consistent with the finding that PHD1 (EglN2, one of prolyl hydroxylases that modify HIFα) was the primary hydroxylase that modifies RPB1, levels of RPB1 hydroxylation correlated with levels of PHD1 in kidney cancer (Yi et al., 2010). Thus the contribution of RPB1 hydroxylation and pVHL-dependent ubiquitination to kidney cancer remains unclear and awaits further investigation.

In addition to RPB1, Na et al. discovered a novel pVHL-interacting protein, human RNA polymerase II seventh subunit (hsRPB7) by performing yeast two-hybrid screening from a kidney cDNA library. hsRPB7 bound to the 54–113 amino acid regions of pVHL, a part of VHL β-domain responsible for substrate recognition (Na et al., 2003). Interestingly, two representative VHL β-domain mutants (P86H and Y98H) showed decreased binding to hsRPB7 compared to wild type. hsRPB7 underwent VHL-dependent ubiquitination and proteasome-dependent degradation. As a functional readout, hsRPB7 can positively regulate VEGF expression, an effect that was ameliorated by overexpressing VHL in kidney cancer cells. However, in this paper, it was not clear whether hydroxylation would play a role in hsRPB7’s degradation by pVHL E3 ligase complex. It will also be critical to identify the molecular mechanism by which hsRPB7 regulates the expression of specific genes such as VEGF.

**PROTEIN KINASE C**

Protein kinase C (PKC) is a superfamily of phospholipid-activated serine/threonine kinase. Activation of canonical PKC family members by 12-O-tetradecanoylphorbol-13-acetate (TPA) can lead to various cellular responses, such as change of cell morphology and increased cell proliferation (Hata et al., 1993; Table 1). Various PKC family members were reported to bind to VHL, and this led to their ubiquitination and degradation. Although PKCζ was found to interact with the β domain of pVHL, its overall protein level was not affected by pVHL status (Iturrizoz et al., 2006). Instead it was PKCζII that was reported to be a pVHL substrate, and its c-terminus was important for VHL-dependent proteasome degradation (Iturrizoz and Parker, 2007). While wild type pVHL could promote the degradation of PKCζII efficiently, some tumor-derived VHL mutants (such as Y98H, G162W, and R167W) failed to do so. However, it remained unclear whether PKCζII was a direct substrate for pVHL complex, and whether proline hydroxylation played a role in the turnover of PKCζII.

Protein kinase Cζ/4RA contains point mutations that render it partially and constitutively active (Akimoto et al., 1996). The active form of PKCζ bound to pVHL tighter than its wild type
Table 1 | A brief description of the pVHL substrates and the types of cancer they are involved in.

<table>
<thead>
<tr>
<th>Gene name</th>
<th>Biological functions</th>
<th>Types of cancer involved</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>HIFα (HIF1, 2, and 3α)</td>
<td>Mediate transcriptional adaptation to oxygen deprivation by enhancing metabolic change, migration, and angiogenesis</td>
<td>All types of cancer</td>
<td>Semenza (2010)</td>
</tr>
<tr>
<td>EGFR (epidermal growth factor receptor)</td>
<td>Activate Ras/RAF/MEK/ERK and PI3K/PDK1/Akt1 pathways; promote cell proliferation; and resistance to apoptosis</td>
<td>All types of cancer</td>
<td>Jorissen et al. (2003), Yarden and Slwikowski (2001)</td>
</tr>
<tr>
<td>RPB1 (large subunit of RNA polymerase II)</td>
<td>The largest subunit of RNA polymerase II, the polymerase responsible for synthesizing messenger RNA in eukaryotes</td>
<td>Kidney cancer</td>
<td>Yi et al. (2010)</td>
</tr>
<tr>
<td>RPB7 (RNA polymerase II seventh subunit)</td>
<td>The seventh largest subunit of RNA polymerase II that reportedly increases VEGF expression</td>
<td>Kidney cancer</td>
<td>Na et al. (2003)</td>
</tr>
<tr>
<td>aPKC (atypical protein kinase C)</td>
<td>Activates MAPK and upregulate VEGF expression (PKCα); phosphorolates MUC1 and potentiates β-catenin signaling (PKCα); increases cancer cell migration (PKCα); acts as endogenous inhibitors of tight junction formation (PKCζII)</td>
<td>Breast cancer</td>
<td>Pal et al. (1997), Ren et al. (2002), Razorenova et al. (2011), Reno et al. (2008), Parkinson et al. (2004)</td>
</tr>
<tr>
<td>SPRY2 (sprouty2)</td>
<td>Antagonizes the activated receptor tyrosine kinases and downregulates angiogenesis</td>
<td>Breast cancer</td>
<td>Lee et al. (2001), Lo et al. (2004), Fong et al. (2006), McKie et al. (2005), Sutterluty et al. (2007), Feng et al. (2011)</td>
</tr>
<tr>
<td>β2AR (β-adrrenergic receptor II)</td>
<td>Mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. involved in cardiovascular functions and apoptosis</td>
<td>Currently not known</td>
<td>Rockman et al. (2002)</td>
</tr>
<tr>
<td>MYBBP1A (Myb-binding protein p160)</td>
<td>May activate or repress transcription through interactions with DNA-binding proteins</td>
<td>Head and neck squamous cell carcinoma</td>
<td>Diaz et al. (2007), Tavner et al. (1998), Acuna Sanhueza et al. (2012)</td>
</tr>
</tbody>
</table>

counterpart, and this led to its preferential ubiquitination by VHL E3 ligase complex (Okuda et al., 2001).

Atypical PKCζ interacted with ASIP/PAR-3 and PAR-6 and was important for the maintenance of the tight junctions and the cell polarity in epithelial cells (Suzuki et al., 2001). In another epithelial cell line HC11 PKCζII was critical to maintain the cells in a non-differentiated state characterized by the absence of tight junctions and cell overgrowth (Parkinson et al., 2004). Since pVHL was reported to bind and degrade several PKC family members, it was reasonable to hypothesize that pVHL can affect actin and cytoskeletal organization, tight junction formation and cell polarity, which were often found dysregulated in cancer cells. Further study is needed to investigate the functional role of the VHL–PKCs axis in kidney cancer.

**SPROUTY2**

Sprouty2 (SPRY2) is one of four mammalian sprouty family members (SPRY1–4; Hacohen et al., 1998). Previous research showed that SPRY family members negatively regulated the activities of receptor tyrosine kinase and reduced angiogenesis (Lee et al., 2001; Table 1). Anderson et al. (2011) reported that hypoxia increased SPRY2 protein levels in various cancer cells, and it did so mainly through increased SPRY2 protein stability. While knockdown of PHD1 or PHD3 increased SPRY2 protein levels, overexpression of all three PHD isoforms (PHD1, 2, and 3) decreased its protein levels. By mass spectrometry, three potential prolyl hydroxylation sites were identified (P18, 144, and 160). Mutating these three Proline residues to Alanine residues significantly decreased the binding between SPRY2 and pVHL and produced more stable SPRY2 protein. Functionally, since SPRY2 was reported to have anti-migratory and anti-proliferative effect on cancer cell growth through inhibiting ERK1/2 kinase pathway (Impagnatiello et al., 2001; Yigzaw et al., 2001), suppressing either PHD1 or pVHL blunted the effect of FGF-induced ERK kinase pathway due to increased SPRY2 protein level. In a subset of hepatocellular carcinoma, pVHL protein levels were upregulated, and this led to decrease of SPRY2 protein that contributed to cancer progression (Lin et al., 2008). However, about 70% renal cell carcinomas have defects in pVHL. If the SPRY2 protein levels are upregulated in these tumors as expected, it will be intriguing to find out how this would impact tumorigenesis.

**β2-ADRENERGIC RECEPTOR**

β2-adrenergic receptor (β2AR) is one of the G-protein-coupled receptors (GPCRs). Besides generating second messengers, β2AR plays an important role in control of cardiovascular functions and apoptosis (Rockman et al., 2002; Table 1). Xie et al. (2009) reported that hypoxia can stabilize β2AR protein by inhibiting its ubiquitination. Further findings demonstrated that pVHL E3 ligase complex associated with β2AR protein in vivo, contributing to its ubiquitination and degradation. Mechanistically, prolyl
Myb-BINDING PROTEIN p160 (MYBBP1A)

Using an ICAT (isotope-coded affinity tag) quantitative proteomics technology, Lai et al. identified MYBBP1A as a novel VHL substrate. MYBBP1A is a transcriptional regulator that can activate or suppress gene transcription through interacting with DNA-binding proteins (Tävner et al., 1998; Diaz et al., 2007; Table 1). MYBBP1A was degraded by VHL in a prolyl hydroxylase-dependent manner. Further research showed that MYBBP1A proline 693 site as the potential hydroxylation site that might trigger the interaction with VHL and subsequent degradation (Lai et al., 2011). It remains largely unknown how MYBBP1A might contribute to kidney cancer.

SUMMARY

Proline hydroxylation on HIFα proteins led to their recognition by pVHL, followed by very efficient ubiquitination and proteasomal degradation. Without a functional VHL, HIF pathway is strongly and constitutively active. So far this has been proved to be the most significant and clinically useful tumor suppressor function of pVHL. However, although proline hydroxylation on RPB1, SPRY2, and β2AR also led to pVHL-dependent ubiquitination, this did not automatically cause protein degradation as the ubiquitin chain linkages on them might be different. It is also unclear whether SPRY2 and β2AR are more abundant in VHL-defective renal cancer cells and whether they contribute to tumor growth or maintenance at all.

Interestingly, it is the active forms of EGFR and atypical PKC that are ubiquitinated by pVHL and targeted for degradation. As these kinases have pro-proliferating and anti-survival activities, it is possible that their degradation is also important to pVHL's tumor suppressor function. It remains to be tested whether protein phosphorylations, in addition to proline hydroxylation, also constitute a recognition signal for pVHL.

REFERENCES


Rockman, H. A., Koch, W. J., and Lekiwofski, R. J. (2002). Seven-transmembrane-spanning receptors...


Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Received: 09 January 2012; accepted: 26 March 2012; published online: 12 April 2012.


This article was submitted to Frontiers in Molecular and Cellular Oncology, a specialty of Frontiers in Oncology. Copyright © 2012 Zhang and Yang. This is an open-access article distributed under the terms of the Creative Commons Attribution Non Commercial License, which permits non-commercial use, distribution, and reproduction in other forums, provided that the original authors and source are credited.